Shanghai Nianxing Industrial Co., Ltd
China
Product Name: HS-PEG4-CH2CH2COOtBu
Price: Check
Purity: 97.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

DC Chemicals Limited
China
Product Name: Thiol-PEG4-t-butyl ester
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: HS-PEG4-tBu
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

564476-33-1

564476-33-1 structure

564476-33-1 structure

Name: HS-PEG4-CH2CH2COO<SUP>t</SUP>Bu
Chemical Name: 1-Sulfanyl-3,6,9,12-tetraoxapentadecan-15-oic acid
CAS Number: 564476-33-1
Molecular Formula: C₁₅H₃₀O₆S
Molecular Weight: 282.35400
Catalog: Signaling Pathways PROTAC PROTAC Linker
Create Date: 2016-01-15 13:55:49
Modify Date: 2025-08-25 11:11:10
Thiol-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

Name	1-Sulfanyl-3,6,9,12-tetraoxapentadecan-15-oic acid
Synonyms	15-mercapto-4,7,10,13-tetraoxapentadecanoic acid tert-butyl ester 15-Keto-1-dehydro-testololacton

Description	Thiol-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PROTAC >> PROTAC Linker
Target	PEGs Alkyl/ether
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
References	[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Molecular Formula	C₁₅H₃₀O₆S
Molecular Weight	282.35400
Exact Mass	282.11400
PSA	113.02000
LogP	0.45730

564476-32-0 structure

564476-32-0

~85%

564476-33-1 structure

564476-33-1

Literature: ImmunoGen, Inc. Patent: US2004/1838 A1, 2004 ;

778596-19-3 structure

778596-19-3

~%

564476-33-1 structure

564476-33-1

Literature: Miller, Michael L.; Roller, Elizabeth E.; Zhao, Robert Y.; Leece, Barbara A.; Ab, Olga; Baloglu, Erkan; Goldmacher, Victor S.; Chari, Ravi V. J. Journal of Medicinal Chemistry, 2004 , vol. 47, # 20 p. 4802 - 4805

112-60-7 structure

112-60-7

~%

564476-33-1 structure

564476-33-1

Literature: Miller, Michael L.; Roller, Elizabeth E.; Zhao, Robert Y.; Leece, Barbara A.; Ab, Olga; Baloglu, Erkan; Goldmacher, Victor S.; Chari, Ravi V. J. Journal of Medicinal Chemistry, 2004 , vol. 47, # 20 p. 4802 - 4805

1663-39-4 structure

1663-39-4

~%

564476-33-1 structure

564476-33-1

Literature: Miller, Michael L.; Roller, Elizabeth E.; Zhao, Robert Y.; Leece, Barbara A.; Ab, Olga; Baloglu, Erkan; Goldmacher, Victor S.; Chari, Ravi V. J. Journal of Medicinal Chemistry, 2004 , vol. 47, # 20 p. 4802 - 4805

518044-32-1 structure

518044-32-1

~%

564476-33-1 structure

564476-33-1

Literature: Miller, Michael L.; Roller, Elizabeth E.; Zhao, Robert Y.; Leece, Barbara A.; Ab, Olga; Baloglu, Erkan; Goldmacher, Victor S.; Chari, Ravi V. J. Journal of Medicinal Chemistry, 2004 , vol. 47, # 20 p. 4802 - 4805

581065-94-3 structure

581065-94-3

~%

564476-33-1 structure

564476-33-1

Literature: Miller, Michael L.; Roller, Elizabeth E.; Zhao, Robert Y.; Leece, Barbara A.; Ab, Olga; Baloglu, Erkan; Goldmacher, Victor S.; Chari, Ravi V. J. Journal of Medicinal Chemistry, 2004 , vol. 47, # 20 p. 4802 - 4805

Precursor 6
564476-32-0 778596-19-3 112-60-7 1663-39-4
518044-32-1 581065-94-3
DownStream 0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.